The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
BellmuntJ, de WitR, AlbanellJ, BaselgaJ.A feasibility study of carboplatin with fixed dose of gemcitabine in “unfit” patients with advanced bladder cancer. Eur J Cancer. 2001;37(17):2212–2215.
2.
ShannonC, CrombieC, BrooksA, LauH, DrummondM, GurneyH.Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: Effective treatment of patients with poor prognostic features. Ann Oncol. 2001;12(7):947–952.
3.
Nogue-AliguerM, CarlesJ, ArriviA, Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: An alternative therapy. Cancer. 2003;97(9):2180–2186.
4.
LinardouH, AravantinosG, EfstathiouE, Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the hellenic co-operative oncology group. Urology. 2004;64(3):479–484.
5.
DogliottiL, CarteniG, SienaS, Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: Results of a randomized phase 2 trial. Eur Urol. 2007;52(1):134–141.
6.
ParkJH, LeeSW, KimHS, Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract. Cancer Chemother Pharmacol. 2013;71(4):1033–1039.
KoieT, OhyamaC, HashimotoY, Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscleinvasive bladder cancer, including those unfit for cisplatin: A prospective single-arm study. Int J Clin Oncol. 2013;18(4): 724–730.
9.
IwasakiK, ObaraW, KatoY, TakataR, TanjiS, FujiokaT.Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer. Jpn J Clin Oncol. 2013;43(2): 193–199.
10.
CalvertAH, NewellDR, GumbrellLA, Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748–1756.
11.
CockcroftDW, GaultMH.Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
12.
CathomasR, HarleA, MeadGM, Glomerular filtration rate (GFR) in patients with stage I testicular seminoma treated with adjuvant carboplatin: A comparison of six formulae compared to a radioisotope gold standard. J Clin Oncol. 2007;25(18 suppl): abstract15504.
13.
BoumedienF, ArsenaultY, LeTarteN.Impact of weight and creatinine measurements in carboplatin dosing. J Clin Oncol. 2012;30(15 suppl): abstract e13027.
14.
EkhartC, RodenhuisS, SchellensJHM, BeijnenJH, HuitemaADR. Carboplatin dosing in overweight and obese patients with normal renal function. Does weight matter?Cancer Chemother Pharmacol. 2009;64(1):115–122.
15.
HerringtonJD, TranHT, RiggsMW.Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥ 27 or cachexia. Cancer Chemother Pharmacol. 2006;57(2):241–247.
16.
DevineBJ.Gentamycin therapy. Drug Intell Clin Pharm. 1974;8:650–655.
17.
KaagD.Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors. Lung Cancer. 2013;79(1):54–58.
18.
O'CearbhaillR.New guidelines for carboplatin dosing. Gyn Oncol Group Newsletter. 2012;(Spring issue):5–6.
MyersAL, ZhangYP, KawediaJD, Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags [published online ahead of print August 12, 2014]. J Oncol Pharm Pract. doi: 1078155214546016.
21.
TemperoM, PlunkettW, Ruiz Van HaperenV, Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21(18):3402–3408.
RoilaF, HerrstedtJ, AaproM, Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):232–243.
24.
GelingO, EichlerHG.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289–1294.
